TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03704519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: 300 mg tablet darolutamide, once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: 300 mg tablet darolutamide, once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: 300 mg tablet darolutamide, once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: 300 mg tablet darolutamide, once orally
Study: NCT00002494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT03704519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: 300 mg tablet darolutamide, once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY1841788)
Description: 300 mg tablet darolutamide, once orally
Study: NCT00002494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study: NCT03704519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 4 x 40 mg capsules, once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 4 x 40 mg capsules, once orally
Study: NCT02255565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Quillivant XR
Description: Oral suspension dose once a day increasing to a 20mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate Dose Quillivant XR
Description: Oral suspension dose once a day increasing to a 40mg dose
Study: NCT03704519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 4 x 40 mg capsules, once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 4 x 40 mg capsules, once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 4 x 40 mg capsules, once orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 4 x 40 mg capsules, once orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 placebo tablets, once orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 placebo tablets, once orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 placebo tablets, once orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 placebo tablets, once orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 placebo tablets, once orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 placebo tablets, once orally
Study: NCT01720706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA Loosely wound thermal coil
Description: This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA Loosely wound thermal coil
Description: This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode.
Study: NCT02661932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis.
Study: NCT02045498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capnography feedback
Description: capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
Study: NCT01053611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 6 ng/ml
Study: NCT02550548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP infusion
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
Study: NCT04127552

Intervention type: PROCEDURE
Intervention: Adrenalectomy
Description: Adrenalectomy accordint to 2016 ESE guidelines
Study: NCT03371316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ViaShield
Description: Anti-adhesion scores using amnion patch
Study: NCT02139735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: 3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: 3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound associated with stretching
Description: 3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound associated with stretching
Description: 3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
Study: NCT01736449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT01181232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem MR
Description: oral
Study: NCT01204229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Cognitive Intervention for Drinkers (MCID)
Description: Integrate social anxiety/ depression and drinking intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Description: Integrate drinking intervention
Study: NCT02719119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monthly Endoscopic Variceal Ligation (EVL)
Description: Patients in this group will underwent endoscopic variceal ligation monthly.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bi-weekly Endoscopic Variceal Ligation (EVL)
Description: Patients in this group will underwent endoscopic variceal ligation bi-weekly.
Study: NCT02928003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung surgery
Description: Genetic analysis and questionnaires
Study: NCT01181232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem IR
Description: oral
Study: NCT03998059

Intervention type: PROCEDURE
Intervention: splenectomy
Description: These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
Study: NCT00330044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premetrexed (Alimta)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01680692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine
Description: Infusion of local anesthetic for post-operative analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: Infusion of local anesthetic for post-operative analgesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Femoral Nerve Catheter
Description: Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Femoral Nerve Catheter
Description: Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Tibial Nerve Catheter
Description: Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
Study: NCT00300482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-335
Description: 135 mg, daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin Calcium
Description: Daily, 12 weeks, see Arm Description for dosage information

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for information regarding placebo type

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for information regarding placebo type

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for information regarding placebo type

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily, 12 weeks, see Arm Description for information regarding placebo type
Study: NCT01878110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMB
Study: NCT03168243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Energy High Protein Tube Feed
Description: Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
Study: NCT01389531

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rigid bronchoscopy
Description: The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
Study: NCT02550548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP infusion
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP infusion
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Description: after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ex-9 infusion
Description: Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
Study: NCT03698747

Intervention type: DEVICE
Intervention: McDESPOT
Description: myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
Study: NCT02515123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Motion System
Description: E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham E-Motion System
Description: The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
Study: NCT01317966

Intervention type: DRUG
Intervention: rhIL-11
Description: Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
Study: NCT03494413

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transpharyngeal Doppler sonography (TPS)
Description: Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transpharyngeal Doppler sonography (TPS)
Description: Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional colour-coded Duplex sonography (CDS)
Description: Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional colour-coded Duplex sonography (CDS)
Description: Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery
Study: NCT01942915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cells
Description: Participants will be transplanted with umbilical cord blood mononuclear cells.
Study: NCT02265120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
Study: NCT04348669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-yoga
Description: Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
Study: NCT03138499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Specified dose on specified days
Study: NCT03836651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)
Description: Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
Study: NCT00002494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT01520675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: Drainage procedure
Study: NCT03415698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
Study: NCT01520675

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy
Description: pancreatic sphincterotomy, removal of calculi, stenting, ESWL
Study: NCT01017289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantum
Description: Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
Study: NCT03963076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)
Description: One spray of nasal hypertonic spray morning and evening every day during 30 days
Study: NCT02842255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibrate the oximeter ALTITRAINER200®
Description: During normoxic condition and four situations of hypoxia.
Study: NCT03415698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
Study: NCT03745352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study: NCT02981173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.143 mg/kg Psilocybin or 10 mg Psilocybin
Description: 0.143 mg/kg psilocybin capsule (weight-based option) or 10 mg psilocybin capsule (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.0143 mg/kg Psilocybin or 1 mg Psilocybin
Description: 0.0143 mg/kg psilocybin capsule (weight-based option) or 1 mg psilocybin (fixed-dose option) ingested on each of three test days (5 days apart +/- 1-2 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
Study: NCT03745352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study: NCT01034371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive direct coronary artery bypass
Description: MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI-Drug eluting stents
Description: PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-pump coronary artery bypass
Description: Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
Study: NCT02523742

Intervention type: DEVICE
Group type: OTHER
Intervention: IMRf
Study: NCT00513071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00619346

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, BID X 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pafuramidine maleate
Description: Pafuramidine maleate, 100 mg tablet BID X 14 days
Study: NCT02523742

Intervention type: DEVICE
Group type: OTHER
Intervention: IMRf

Intervention type: OTHER
Group type: OTHER
Intervention: language task and a reference task (rest and Tamil)

Intervention type: OTHER
Group type: OTHER
Intervention: language task and a reference task (rest and Tamil)
Study: NCT03918213

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-Resolution anorectal manometry with the use of solid-state catheter
Description: High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study